Pharmaceuticals
Innovent Provides Updates on Extended Follow-up on Sintilimab for Relapsed/Refractory Classical Hodgkin's Lymphoma
SUZHOU, China, June 4, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the results of extended follow-up on sintilimab, the anti-PD-1 antibody that co-deve...
2019-06-04 08:00
10272
Innovent Provides Update on Sintilimab in Combination with CAPOX for First-Line Treatment of Patients with Gastric or Gastroesophageal Junction Carcinoma (GC/GEJC)
SUZHOU, China, June 4, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the preliminary results of efficacy and safety of sintilimab, the anti-PD-1 antibody...
2019-06-04 08:00
10737
Ascentage Pharma presents new clinical data of apoptosis-targeted drug candidates APG-115 and APG-1387 at 2019 ASCO
SUZHOU, China and CHICAGO, June 3, 2019 /PRNewswire/ -- Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the company presented new data of two apoptosis-ta...
2019-06-04 07:00
2428
Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa
Highlights: * 42% investigator-assessed ORR achieved in patients with advanced PEComa – a rare sarcoma with no currently approved therapy * First prospective clinical study in advanced PEComa shows durable responses with nab-sirolimus with a manageable safety profile * 62% of all responding...
2019-06-04 06:39
2508
Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations
ASCO Abstract # Tepotinib (MET kinase inhibitor): 9005 Not intended for UK- , Canada- or US-based media DARMSTADT, Germany, June 4, 2019 /PRNewswire/ -- * Alterations of the MET signaling pathway are present in 3-5% of non-small cell lung cancer patients and correlate with poor prognosis * N...
2019-06-04 02:16
3082
Frost & Sullivan Publishes Q1 Update on Kadimastem
Continues its plans as expected; Ministry of Health approval for central experiment; financing is required to continue operations at the beginning of 2020; received Orphan Drug Designation from the FDA; target price unchanged. TEL AVIV, Israel, June 3, 2019 /PRNewswire/ -- The TASE analysis proje...
2019-06-03 21:24
1640
CStone submits new drug application for TIBSOVO(R) in Taiwan for the treatment of relapsed/refractory AML
HONG KONG, June 2, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) announced that a new drug application (NDA) for TIBSOVO® (ivosidenib) has been submitted by a third-party to the Taiwan Food and Drug Administration (TFDA) as the first to-be-approved treatment of adult patients...
2019-06-03 11:45
5754
Updated Results on Neoadjuvant PD-1 Blockade with Sintilimab in Resectable Squamous Non-Small Cell Lung Cancer (sqNSCLC) at ASCO, Led by Professor Jie He, Dean of the Cancer Hospital of the Chinese Academy of Medical Sciences
SUZHOU, China, June 3, 2019 /PRNewswire/ -- The preliminary results of efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer (sqNSCLC) (ChiCTR-OIC-17013726), led by ProfessorJie He, Dean of the Cancer Hospital of the Chinese Academy of ...
2019-06-03 08:00
11780
Innovent Provides Key Results Update of IBI305 (Biosimilar Product Candidate of Bevacizumab) Compared with Bevacizumab
SUZHOU, China, June 3, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the study results for efficacy and safety of IBI305 (biosimilar of bevacizumab) comp...
2019-06-03 08:00
3268
Sihuan Pharm Post-launching Large-scale Clinical Trials of Cinepazide Maleate Injection were Completed With Efficacy Verified
HONG KONG, June 1, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) the largest cardio-cerebral vascular ("CCV") drug manufacturer inChina's prescription drug market, announced that the Group has completed the post-launch clinical trials of "Cinepazide Maleate Inject...
2019-06-01 11:18
1917
Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business
PHILADELPHIA, May 31, 2019 /PRNewswire/ -- Iovance Biotherapeutics, a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, has expanded its relationship with WuXi AppTec's Advanced Therapies Business Unit (WuXi ATU). Wu...
2019-05-31 20:00
2925
Innovent Provides Update on Phase Ib Study of Sintilimab in Combination with Chemotherapy for First-line Advanced or Metastatic Non-small Cell Lung Cancer
SUZHOU, China, May 31, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the preliminary results of sintilimab, the anti-PD-1 antibody that co-developed with...
2019-05-31 08:00
4235
Conagen announces formation of Scientific Advisory Board
Board includes five world-leading scientists in the fields of Synthetic Biology and Applied Molecular Biology BEDFORD, Massachusetts, May 30, 2019 /PRNewswire/ -- Conagen Inc., a vertically integrated synthetic biology and fermentation company, announced today the formation of a new scientific ...
2019-05-30 20:00
2166
CartiHeal's Agili-C™ Implant Enhances In-vitro Osteogenic Differentiation of Human Bone Marrow-derived Mesenchymal Stem Cells
KFAR SABA, Israel, May 30, 2019 /PRNewswire/ -- CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of osteochondral and chondral defects, announced today the publication of anin-vitro study demonstrating that the Agili-C™ implant enhances osteogenic differentiation of human...
2019-05-30 20:00
2002
Luye Pharma's Rykindo® NDA Filing Accepted by the U.S. FDA
SHANGHAI, May 30, 2019 /PRNewswire/ -- Rykindo® (LY03004), Luye Pharma's innovative, independently developed Extended-Release Microspheres formulation for injection, is one step closer to going on the U.S. market. The US Food and Drug Administration (FDA) has completed the filing review and acce...
2019-05-30 13:09
2689
PHS Health Solutions Unveils Company Rebrand to Amplity Health
New Brand Identity Sets the Stage for a New Pure-play Commercialization Partner to the Pharmaceutical Industry YARDLEY, Pennsylvania, May 29, 2019 /PRNewswire/ -- PHS Health Solutions (PHS), a leading pharmaceutical contract commercial organization with an exemplary 35-year track record as ...
2019-05-29 22:00
1706
Sihuan Pharm Obtained Phase I to III Clinical Trial Approval for the Third Generation of EGFR Inhibitor XZP-5809
HONG KONG, May 29, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), the largest cardio-cerebral vascular ("CCV") drug manufacturer inChina's prescription drug market, announced the third generation of EGFR inhibitor XZP-5809, a Category 1 innovative drug developed by t...
2019-05-29 18:00
4954
IMI launches IMI Corporate Wellness amidst growing concerns for professionals' wellbeing.
HONG KONG, May 28, 2019 /PRNewswire/ -- Integrated Medicine Institute (IMI), Hong Kong's largest natural and integrated medicine clinic, today announced the official launch of its corporate wellness arm. Already at work in global organizations with a presence inHong Kong, IMI Corporate Wellness s...
2019-05-28 09:15
3533
After $7.1 Billion Sale Of Frutarom, Ori Yehudai To Join The Sade Group As Active Chairman and Investor
NESS ZIONA, Israel, May 27, 2019 /PRNewswire/ -- Ori Yehudai: "I took a company worth$3 million and sold it to IFF at $7.1 billion in 2018. In my opinion, the success of our cannabis company will be to build an industrial pharmaceutical company with the strictest standards, we had two such plants...
2019-05-27 20:05
2566
Sihuan Pharm Becomes the First Chinese Company that was Granted Approval for "Non-PVC Solid-Liquid Double Chamber Bag for Ceftazidime/Sodium Chloride Injection"
HONG KONG, May 27, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) ("Sihuan Pharmaceutical" or the "Group"), the largest cardio-cerebral vascular ("CCV") drug manufacturer in China's prescription drug market, announced the "non-PVC solid-liquid double chamber bag for ...
2019-05-27 17:08
5077
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 327 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 321 media titles]
2024-05-15 12:00
Innomix and World Castle Association Pioneer LBMR project at Zhangbi Fortress
[Picked up by 311 media titles]
2024-05-20 13:48
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 308 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 278 media titles]
2024-05-16 09:39
Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
12807
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
2024-05-16 15:00
11515
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
2024-05-16 09:39
10824
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
9635
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
2024-05-17 07:00
9150